Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The evidence for venetoclax shows comparable efficacy to existing options, particularly in the context of the SACT dataset, which indicates a median overall survival of 43.1 months. However, the lack of direct comparison with best supportive care and uncertainties regarding the benefit of adding rituximab limit the strength of the evidence.
Cost effectiveness
The ICER for venetoclax is around £50,000 per QALY gained, which is considered acceptable for end-of-life treatments. This suggests that the treatment is marginally cost-effective, although the cost-effectiveness is context-dependent.
Quality of life
The appraisal highlights that chronic lymphocytic leukaemia (CLL) significantly impacts quality of life, and venetoclax is considered an important treatment option for patients who have limited alternatives. While specific HRQoL data is not detailed, the recognition of the treatment’s value suggests moderate improvements.
Supporting Domains
Safety and Adverse Effects
The safety profile of venetoclax is generally acceptable, with manageable adverse events. The committee noted that the treatment is well-tolerated, although some concerns about adverse effects exist, particularly when combined with other therapies.
Comparator Selection
Best supportive care was deemed an appropriate comparator, but the lack of direct comparisons with this standard limits the robustness of the evidence. The committee acknowledged the challenges in defining best supportive care accurately.
Patient Population and Subgroups
The patient population for venetoclax is well-defined, focusing on adults with specific genetic markers or treatment failures. The committee noted that the population is representative of those who would typically receive this treatment.
Care Pathway Integration
Venetoclax can be integrated into existing treatment pathways with minor adjustments. The committee noted that it fits well within the current treatment landscape for CLL, requiring no significant changes to infrastructure.
Resource Use and Cost Implications
The budget impact is manageable, particularly with the commercial arrangement in place. The committee acknowledged that while there is a notable cost, it is justifiable given the treatment’s benefits.
Evidence Quality and Robustness
The evidence base relies heavily on the SACT dataset and previous trials, which have limitations. While the data is the best available, there are gaps and uncertainties that affect the overall robustness.
Uncertainty, Sensitivity, and Broader Impacts
The committee recognized that while there are uncertainties, particularly regarding the long-term efficacy and safety of venetoclax, the treatment addresses a significant unmet need in CLL, which mitigates some concerns.
